GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Integra Lifesciences Holdings Corp (NAS:IART) » Definitions » Piotroski F-Score

Integra Lifesciences Holdings (Integra Lifesciences Holdings) Piotroski F-Score : 6 (As of May. 14, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Integra Lifesciences Holdings Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Integra Lifesciences Holdings has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Integra Lifesciences Holdings's Piotroski F-Score or its related term are showing as below:

IART' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 6   Max: 9
Current: 6

During the past 13 years, the highest Piotroski F-Score of Integra Lifesciences Holdings was 9. The lowest was 4. And the median was 6.


Integra Lifesciences Holdings Piotroski F-Score Historical Data

The historical data trend for Integra Lifesciences Holdings's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integra Lifesciences Holdings Piotroski F-Score Chart

Integra Lifesciences Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 6.00 7.00 8.00 4.00

Integra Lifesciences Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.00 5.00 5.00 4.00 6.00

Competitive Comparison of Integra Lifesciences Holdings's Piotroski F-Score

For the Medical Devices subindustry, Integra Lifesciences Holdings's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Integra Lifesciences Holdings's Piotroski F-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Integra Lifesciences Holdings's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Integra Lifesciences Holdings's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was 4.184 + 19.497 + 19.834 + -3.281 = $40 Mil.
Cash Flow from Operations was 28.279 + 26.77 + 58.75 + 15.756 = $130 Mil.
Revenue was 381.267 + 382.421 + 397.039 + 368.872 = $1,530 Mil.
Gross Profit was 207.026 + 218.345 + 226.493 + 206.834 = $859 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(3742.399 + 3777.601 + 3739.371 + 3781.988 + 4078.224) / 5 = $3823.9166 Mil.
Total Assets at the begining of this year (Mar23) was $3,742 Mil.
Long-Term Debt & Capital Lease Obligation was $170 Mil.
Total Current Assets was $1,416 Mil.
Total Current Liabilities was $302 Mil.
Net Income was 44.788 + 49.915 + 52.946 + 24.226 = $172 Mil.

Revenue was 397.815 + 385.191 + 398.022 + 380.846 = $1,562 Mil.
Gross Profit was 249.411 + 236.746 + 250.085 + 232.871 = $969 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(3671.997 + 3752.862 + 3807.013 + 3889.758 + 3742.399) / 5 = $3772.8058 Mil.
Total Assets at the begining of last year (Mar22) was $3,672 Mil.
Long-Term Debt & Capital Lease Obligation was $1,597 Mil.
Total Current Assets was $1,029 Mil.
Total Current Liabilities was $282 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Integra Lifesciences Holdings's current Net Income (TTM) was 40. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Integra Lifesciences Holdings's current Cash Flow from Operations (TTM) was 130. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=40.234/3742.399
=0.01075086

ROA (Last Year)=Net Income/Total Assets (Mar22)
=171.875/3671.997
=0.04680696

Integra Lifesciences Holdings's return on assets of this year was 0.01075086. Integra Lifesciences Holdings's return on assets of last year was 0.04680696. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Integra Lifesciences Holdings's current Net Income (TTM) was 40. Integra Lifesciences Holdings's current Cash Flow from Operations (TTM) was 130. ==> 130 > 40 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=170.082/3823.9166
=0.04447848

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=1596.622/3772.8058
=0.4231922

Integra Lifesciences Holdings's gearing of this year was 0.04447848. Integra Lifesciences Holdings's gearing of last year was 0.4231922. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=1415.65/302.394
=4.68147516

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=1029.482/282.293
=3.64685628

Integra Lifesciences Holdings's current ratio of this year was 4.68147516. Integra Lifesciences Holdings's current ratio of last year was 3.64685628. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Integra Lifesciences Holdings's number of shares in issue this year was 77.735. Integra Lifesciences Holdings's number of shares in issue last year was 82.323. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=858.698/1529.599
=0.56138766

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=969.113/1561.874
=0.62048091

Integra Lifesciences Holdings's gross margin of this year was 0.56138766. Integra Lifesciences Holdings's gross margin of last year was 0.62048091. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=1529.599/3742.399
=0.40872152

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=1561.874/3671.997
=0.4253473

Integra Lifesciences Holdings's asset turnover of this year was 0.40872152. Integra Lifesciences Holdings's asset turnover of last year was 0.4253473. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+1+1+0+0
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Integra Lifesciences Holdings has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Integra Lifesciences Holdings  (NAS:IART) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Integra Lifesciences Holdings Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Integra Lifesciences Holdings's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Integra Lifesciences Holdings (Integra Lifesciences Holdings) Business Description

Traded in Other Exchanges
Address
1100 Campus Road, Princeton, NJ, USA, 08540
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman specialty surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
Executives
Chantal Veillon-berteloot officer: EVP & CHRO 1100 CAMPUS ROAD, PRINCETON NJ 08540
Jeffrey Mosebrook officer: SVP, Fin & PAO 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Lea Daniels Knight officer: EVP & CFO 1100 CAMPUS ROAD, PRINCETON NJ 08540
Eric Schwartz officer: Corp VP, Gen Counsel & Sec C/O ERESEARCHTECHNOLOGY, INC., 1818 MARKET STREET, SUITE 1000, PHILADELPHIA PA 19103
Witte Jan De director, officer: President & CEO C/O RESMED INC., 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123
Michael J. Mcbreen officer: Executive VP & President, CSS 1100 CAMPUS ROAD, PRINCETON NJ 08540
Harvinder Singh officer: Exec VP & PRES, International 1100 CAMPUS ROAD, PRINCETON NJ 08540
Lisa Evoli officer: Chief Human Resources Officer 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Raymond G. Murphy director 14604 CARROLTON ROAD, ROCKVILLE MD 20853
Renee Wonlai Lo director 1100 CAMPUS ROAD, PRINCETON NJ 08540
Glenn Coleman officer: CVP, CHIEF FINANCIAL OFFICER C/O DENTSLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Tru St Partnership, L.p. 10 percent owner 795 EAST LANCASTER AVE., STE. 200, VILLANOVA PA 19085
Peter J Arduini officer: President & COO 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Shaundra Clay director 1100 CAMPUS ROAD, PRINCETON NJ 08540
Stuart Essig director, officer: President and CEO 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536

Integra Lifesciences Holdings (Integra Lifesciences Holdings) Headlines